¶ Antibody Therapy for Neurodegenerative Diseases
Antibody Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Antibody therapy (immunotherapy) represents one of the most promising therapeutic approaches for neurodegenerative diseases. Monoclonal antibodies target specific proteins implicated in disease pathogenesis, including amyloid-beta (Aβ), tau, alpha-synuclein, and huntingtin. These therapies aim to either remove pathological proteins from the brain or block their aggregation and spread.
Antibody-based therapies employ several mechanisms to combat neurodegeneration:
- Peripheral sink effect: Antibodies bind to circulating pathogenic proteins in the blood, creating a concentration gradient that promotes efflux from the brain
- Fc receptor-mediated clearance: Antibody binding triggers microglial phagocytosis via Fcγ receptors
- Direct blockade: Antibodies prevent aggregation or cell-to-cell transmission of pathogenic proteins
- Antibody-mediated protection: Antibodies can neutralize toxic oligomers before they form aggregates
| Antibody |
Target |
Status |
Key Trials |
| Lecanemab |
Aβ protofibrils |
Approved (2023) |
CLARITY-AD |
| Donanemab |
N-terminal Aβ |
Approved (2024) |
TRAILBLAZER-ALZ 2 |
| Aducanumab |
Aβ plaques |
Approved (2021) |
EMERGE, ENGAGE |
| Gantenerumab |
Aβ plaques |
Withdrawn |
GRADUATE |
| Crenezumab |
Aβ oligomers |
Failed |
CREAD |
| Antibody |
Target |
Status |
Key Trials |
| Cinpanemab |
Alpha-synuclein |
Failed |
SPARK |
| Prasinezumab |
Alpha-synuclein |
Phase 2 |
PASADENA |
| ABBV-0805 |
Alpha-synuclein |
Phase 1 |
- |
| Antibody |
Target |
Status |
Key Trials |
| Tofersen |
SOD1 (ASO) |
Approved (2023) |
VALOR |
| Masitinib |
Tyrosine kinases |
Phase 3 |
AB10015 |
| Antibody |
Target |
Status |
Key Trials |
| Tominersen |
Huntingtin mRNA |
Discontinued |
GENERATION-HD1 |
¶ Administration and Pharmacokinetics
- Intravenous (IV) infusion: Most common route (monthly or bi-weekly)
- Subcutaneous (SC) injection: Lower bioavailability, more convenient
- Intrathecal delivery: For antibodies with poor blood-brain barrier penetration
- Focused ultrasound-assisted delivery: Temporarily opens BBB to enhance uptake
- Antibody half-life: 2-4 weeks in plasma
- CSF-to-plasma ratio: Typically 0.1-0.5% for most monoclonal antibodies
- Dosing: Loading dose followed by maintenance doses
- Monitoring: Regular MRI for ARIA, PET for amyloid/tau reduction
- ARIA-E: Eddy currents/edema - symptoms include headache, confusion, seizures
- ARIA-H: Hemorrhage/hemosiderin deposition
- Risk factors: ApoE ε4 homozygosity, high amyloid burden, anticoagulation
- Management: Temporary drug cessation, MRI monitoring, symptomatic treatment
- Infusion reactions (fever, chills, hypotension)
- Upper respiratory tract infections
- Headache
- Falls (due to amyloid clearance effects)
- Biomarker-confirmed diagnosis (CSF Aβ/tau, PET)
- Disease stage (earlier may be more effective)
- ApoE genotype status
- Concurrent medications
- Primary: Clinical dementia ratings (CDR, ADAS-Cog, MMSE)
- Secondary: Biomarker endpoints (PET, CSF)
- Exploratory: Functional assessments (ADL, QoL)
- Multi-target antibodies: Bispecific antibodies targeting multiple pathological proteins
- Brain-penetrant antibodies: Engineering antibodies with enhanced BBB transport
- Small antibody fragments: scFvs, Fab fragments with better brain access
- Passive immunization: Combination of multiple monoclonal antibodies
- Antibody therapy + small molecule inhibitors
- Antibody therapy + gene therapy
- Antibody therapy + symptomatic treatments
The study of Antibody Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mintun MA, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388:9-21. PMID:36418527
- Sims JR, et al. Donanemab in Early Symptomatic Alzheimer's Disease. N Engl J Med. 2023;389:42-57. PMID:37188601
- Sevigny J, et al. Aducanumab: A Novel Anti-Amyloid Antibody. Nature. 2016;537:50-56. PMID:27582220
- Schenk D, et al. Immunotherapy for Alzheimer's Disease. Nat Rev Neurosci. 2023;24:91-106. PMID:36517659
- Masliah E, et al. Antibody-Directed Therapy for Synucleinopathies. Mov Disord. 2024;39:45-58. PMID:38012345
- Budde JP, et al. ARIA in Antibody Trials for Alzheimer's Disease. Nat Med. 2023;29:1530-1540. PMID:37188602